Organovo Holdings, Inc.

Equities

ONVO

US68620A2033

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-24 EDT			5-day change	1st Jan Change
0.9974 ^USD	+0.65%		-3.17%	-10.14%

04-15	Organovo's fatty liver disease drug meets main goal in mid-stage study	RE
04-15	Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	CI

Organovo Holdings, Inc. Appoints Jonathan Lieber as President, Effective May 13, 2021

May 13, 2021 at 04:06 pm

The Board of Directors of the Organovo Holdings, Inc. appointed Jonathan Lieber as President of the company, effective May 13, 2021. Mr. Jonathan Lieber is currently employed by Danforth Advisors, LLC (“Danforth”), a professional financial consulting services firm.

Latest news about Organovo Holdings, Inc.

Organovo's fatty liver disease drug meets main goal in mid-stage study	04-15	RE
Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	04-15	CI
Organovo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-08	CI
Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings	01-25	CI
Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results	12-06	CI
Organovo Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-09	CI
Organovo Holdings, Inc. Highlights FXR314 Combination Therapy Potential and Plan	11-08	CI
Organovo Holdings, Inc. Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data	23-08-23	CI
Organovo Holdings, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Organovo Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-07-14	CI
Organovo Holdings, Inc. Auditor Raises 'Going Concern' Doubt	23-07-13	CI
North American Morning Briefing : Optimism Set to -2-	23-07-13	DJ
North American Morning Briefing : Fed Hawks Hit -2-	23-07-06	DJ
North American Morning Briefing : Claims Data, GDP -2-	23-06-29	DJ
North American Morning Briefing : Stock Futures -2-	23-06-22	DJ
North American Morning Briefing : Traders Digest -2-	23-06-15	DJ
North American Morning Briefing : Nasdaq Futures -2-	23-06-08	DJ
North American Morning Briefing : Stock Futures -3-	23-02-10	DJ
Organovo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-09	CI
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates	22-11-15	CI
Organovo Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-10	CI
Organovo Holdings, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-11	CI
Organovo Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	22-06-10	CI
Organovo Holdings to Proceed With Target Discovery, Validation for Crohn's Disease After Achieving 3D Tissue Model	22-05-17	MT
Organovo Holdings, Inc. Successfully Advances Its First Inflammatory Bowel Disease Model to the Next Step of Target Discovery and Validation for Crohn’s Disease	22-05-17	CI

Chart Organovo Holdings, Inc.

Duration

Period

More charts

Company Profile

Organovo Holdings, Inc. is a biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). The Company uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ORGANOVO HOLDINGS, INC.	-10.14%	11.36M
MODERNA, INC.	+67.53%	63.85B
IQVIA HOLDINGS INC.	-0.77%	41.83B
LONZA GROUP AG	+45.66%	40.65B
CELLTRION, INC.	-10.72%	27.12B
ICON PUBLIC LIMITED COMPANY	+13.30%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-22.79%	18.69B
BIO-TECHNE CORPORATION	+4.70%	12.73B
UNITED THERAPEUTICS CORPORATION	+24.10%	12.11B
MEDPACE HOLDINGS, INC.	+27.41%	12.07B

Other Biotechnology & Medical Research